Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Penumbra, Inc.    PEN

PENUMBRA, INC.

(PEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
206.23(c) 213.59(c) 223.01(c) 233.04(c) 228.46(c) Last
834 143 597 442 674 623 700 750 510 228 Volume
+4.31% +3.57% +4.41% +4.50% -1.97% Change
More quotes
Financials (USD)
Sales 2020 536 M - -
Net income 2020 -40,2 M - -
Net Debt 2020 - - -
P/E ratio 2020 -208x
Yield 2020 -
Sales 2021 650 M - -
Net income 2021 32,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 263x
Yield 2021 -
Capitalization 8 296 M 8 296 M -
Capi. / Sales 2020 15,5x
Capi. / Sales 2021 12,8x
Nbr of Employees 2 700
Free-Float 93,4%
More Financials
Company
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that... 
More about the company
Notations Surperformance© of Penumbra, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about PENUMBRA, INC.
01/13PENUMBRA : ROSEN, GLOBAL INVESTOR COUNSEL, Continues to Investigate Securities C..
PR
01/11PENUMBRA : Thinking about trading options or stock in Tesla, Biogen, Crocs, Penu..
PR
01/11PENUMBRA : Posts Higher Preliminary Q4 Revenue; Seen Above Wall Street Expectati..
MT
01/11PENUMBRA INC : Results of Operations and Financial Condition, Financial Statemen..
AQ
01/11PENUMBRA : Announces Preliminary Unaudited Revenue for the Fourth Quarter and Fu..
PR
01/07PENUMBRA : Significant Insider Sales in Shares of Penumbra (PEN) Extends the Sel..
MT
01/06INSIDER TRENDS : Insider 90-Day Selling Trend Extended at Penumbra
MT
01/06INSIDER TRENDS : Penumbra Insider Extends 90-Day Selling Trend
MT
2020INVESTOR ALERT : Kirby McInerney LLP Continues Investigation of Shareholder Clai..
BU
2020ONGOING INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating ..
PR
2020PENUMBRA ALERT : Bragar Eagel & Squire, P.C. is Investigating Penumbra, Inc. on ..
BU
2020INSIDER TRENDS : Insider at Penumbra Sells for Tax Adds to 90-Day Selling Trend
MT
2020KESSLER TOPAZ MELTZER & CHECK, LLP I : PEN) Investors
BU
2020PENUMBRA ALERT : Bragar Eagel & Squire, P.C. is Investigating Penumbra, Inc. on ..
BU
2020INVESTOR ALERT : Kaplan Fox Investigates Potential Securities Fraud Penumbra, In..
PR
More news
News in other languages on PENUMBRA, INC.
2019AVIS D'ANALYSTES DU JOUR : LVMH, Rémy Cointreau, Swisscom, Elior, Adidas, Peugeo..
More news
Analyst Recommendations on PENUMBRA, INC.
More recommendations
Chart PENUMBRA, INC.
Duration : Period :
Penumbra, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PENUMBRA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 228,80 $
Last Close Price 228,46 $
Spread / Highest target 13,8%
Spread / Average Target 0,15%
Spread / Lowest Target -10,7%
EPS Revisions
Managers and Directors
NameTitle
Adam Elsesser Chairman, President & Chief Executive Officer
Maggie S. Yuen Chief Financial Officer
David Barry Chief Technology Officer
Pankaj Tiwari Vice President-Information Technology
Ben Tompkins Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PENUMBRA, INC.33.17%8 462
NOVOCURE LIMITED3.41%18 216
MASIMO CORPORATION-2.47%14 411
ASAHI INTECC CO., LTD.-7.57%9 127
GETINGE AB2.03%6 419
SHOCKWAVE MEDICAL, INC.32.07%4 693